Neos Therapeutics to Participate in Two June Conferences

DALLAS and FORT WORTH, Texas, May 31, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, today announced that Vipin K. Garg, Ph.D., President and CEO will present at two upcoming conferences in June.

• Corporate overview at the Jefferies 2018 Healthcare Conference on Wednesday, June 6, 2018 at 8:30 a.m. ET in New York, NY.
• Fireside chat at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 1:00 p.m. ET in New York, NY. 

A live webcast of these presentations will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.

About Neos TherapeuticsNeos Therapeutics, Inc. (NASDAQ: NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex®1, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is available at www.neostx.com.

1Tussionex® is a registered trademark of the UCB Group of Companies.

CONTACTS:

Richard I. EisenstadtChief Financial OfficerNeos Therapeutics(972) 408-1389[email protected]

Sarah McCabe Investor Relations Stern Investor Relations, Inc. (212) 362-1200 [email protected]

You May Also Be Interested In

• Creality Debuts Falcon A1C Desktop Laser Engraver to Make Laser Crafting More Accessible for Home Creators
• World Champion Ruslan Khaletsky Brings Elite Discipline and Science-Backed Formulations to the Booming U.S. Sports Nutrition Market
• Celebrating 30 years in the United States: A look back at Sridhar Rangaswamy’s incredible journey from New Delhi to NASA.